O. Naderer

发表

Design and Rationale of a Randomized, Double-Blind, Placebo-Controlled, Phase 2/3 Study Evaluating Dociparstat in Acute Lung Injury Associated with Severe COVID-19

J. Lasky, R. Lanier, J. Fuloria, 2020, Advances in Therapy.

Investigation of Metabolism and Disposition of GSK1322322, a Peptidase Deformylase Inhibitor, in Healthy Humans Using the Entero-Test for Biliary Sampling

Chester L. Bowen, O. Naderer, Liangfu Chen, 2014, Drug Metabolism and Disposition.

Effects of moderate-dose versus high-dose trimethoprim on serum creatinine and creatinine clearance and adverse reactions

O. Naderer, A. Nafziger, J. Bertino, 1997, Antimicrobial agents and chemotherapy.

The Influence of Norfloxacin and Metronidazole on the Disposition of Mycophenolate Mofetil

E. Heinzen, O. Naderer, Mark W. Johnson, 2005, Journal of clinical pharmacology.

Safety, Tolerability, and Efficacy of GSK1322322 in the Treatment of Acute Bacterial Skin and Skin Structure Infections

W. O'Riordan, O. Naderer, R. Corey, 2014, Antimicrobial Agents and Chemotherapy.

Safety , Tolerability , and Efficacy of GSK 1322322 in the Treatment of Acute Bacterial Skin and Skin Structure Infections

W. O'Riordan, O. Naderer, R. Corey, 2014 .

Penetration of GSK1322322 into Epithelial Lining Fluid and Alveolar Macrophages as Determined by Bronchoalveolar Lavage

Chester L. Bowen, O. Naderer, K. Rodvold, 2013, Antimicrobial Agents and Chemotherapy.

Pharmacokinetics of lamivudine in subjects receiving peritoneal dialysis in end-stage renal failure.

R. Gokal, O. Naderer, H. Iles-Smith, 2007, British journal of clinical pharmacology.

The Effect of Food and Formulation on the Pharmacokinetics, Safety, and Tolerability of GSK1322322 in Healthy Volunteers

O. Naderer, John Zhu, Lori S. Jones, 2014, Clinical pharmacology in drug development.

Safety, tolerability, and pharmacokinetics of oral and intravenous administration of GSK1322322, a peptide deformylase inhibitor

O. Naderer, John Zhu, Lori S. Jones, 2013, Journal of clinical pharmacology.

Safety, tolerability and pharmacokinetics of repeat dosing of the antibiotic GSK1322322, a peptide deformylase inhibitor: a randomized placebo-controlled study.

O. Naderer, John Zhu, Lori S. Jones, 2013, The Journal of antimicrobial chemotherapy.

Effect of H2 Blockade and Food on Single-Dose Pharmacokinetics of GSK1322322, a Peptide Deformylase Inhibitor Antibacterial

O. Naderer, John Zhu, Lori S. Jones, 2013, Antimicrobial Agents and Chemotherapy.

Single-Dose Safety, Tolerability, and Pharmacokinetics of the Antibiotic GSK1322322, a Novel Peptide Deformylase Inhibitor

O. Naderer, John Zhu, Lori S. Jones, 2013, Antimicrobial Agents and Chemotherapy.

Safety , tolerability and pharmacokinetics of repeat dosing of the antibiotic GSK 1322322 , a peptide deformylase inhibitor : a randomized placebo-controlled study

O. Naderer, John Zhu, Lori S. Jones, 2013 .

Retrospective Evaluation of Therapies for Staphylococcus aureus Endocarditis

R. Hershow, O. Naderer, K. Rodvold, 1997, Pharmacotherapy.

A 42-week open-label study to assess the pharmacokinetics, antiretroviral activity, and safety of amprenavir or amprenavir plus ritonavir in combination with abacavir and lamivudine for treatment of HIV-infected patients.

R. Wood, J. Eron, C. Trépo, 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Six-Week Randomized Controlled Trial To Compare the Tolerabilities, Pharmacokinetics, and Antiviral Activities of GW433908 and Amprenavir in Human Immunodeficiency Virus Type 1-Infected Patients

H. Stellbrink, R. Wood, F. Raffi, 2004, Antimicrobial Agents and Chemotherapy.

1421. IV Brincidofovir (BCV): Pharmacokinetics (PK) and Safety of Multiple Ascending Doses (MAD) in Healthy Subjects

Virna J. A. Schuck, Marion E. Morrison, O. Naderer, 2018, Open Forum Infectious Diseases.

Hypersensitivity reactions during therapy with the nucleoside reverse transcriptase inhibitor abacavir.

O. Naderer, G. Pearce, H. Steel, 2001, Clinical therapeutics.

Microbiome Changes in Healthy Volunteers Treated with GSK 1322322 , a Novel Antibiotic Targeting Bacterial Peptide

James R. Brown, G. P. Livi, Elizabeth Thomas, 2015 .

Microbiome Changes in Healthy Volunteers Treated with GSK1322322, a Novel Antibiotic Targeting Bacterial Peptide Deformylase

James R. Brown, G. P. Livi, S. Van Horn, 2014, Antimicrobial Agents and Chemotherapy.

Effects of formulation and dosing strategy on amprenavir concentrations in the seminal plasma of human immunodeficiency virus type 1-infected men.

J. Eron, S. Fiscus, O. Naderer, 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Reduction of plasma mycophenolic acid (MPA) and its glucuronide (MPAG) concentrations with antibiotic treatment

O. Naderer, R. Dupuis, K. Wiwattanawongsa, 1999 .

Application of a Stable Isotope Approach to Evaluate Impact of Changes in Manufacturing Parameters for an Immediate‐Release Tablet

Alan Parr, Manish Gupta, Geoff Badman, 2016, Journal of clinical pharmacology.

Six-Week Randomized Controlled Trial To Compare the Tolerabilities, Pharmacokinetics, and Antiviral Activities of GW433908 and Amprenavir in Human Immunodeficiency Virus Type 1-Infected Patients

H. Stellbrink, R. Wood, F. Raffi, 2004, Antimicrobial Agents and Chemotherapy.

National Survey of Once‐Daily Dosing of Aminoglycoside Antibiotics

S. Crawford, G. Schumock, O. Naderer, 1995, Pharmacotherapy.